145022-92-0
145022-92-0 structure
- Name: Tauro-β-muricholic acid sodium
- Chemical Name: Tauro-β-muricholic acid sodium
- CAS Number: 145022-92-0
- Molecular Formula: C26H44NNaO7S
- Molecular Weight: 537.68
- Catalog: Signaling Pathways Metabolic Enzyme/Protease FXR
- Create Date: 2020-06-01 15:08:17
- Modify Date: 2025-08-25 10:33:53
-
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
| Name | Tauro-β-muricholic acid sodium |
|---|
| Description | Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 40 μM (FXR)[1] |
| In Vitro | T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC50 ~10 μM)[3]. T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells[3]. T-βMCA sodium induces proliferation and DNA damage in Lgr5+ cells[3]. |
| In Vivo | T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression[3]. T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17[3]. Animal Model: APCmin/+ mice[3] Dosage: 400 mg/kg Administration: Oral gavage; twice a week; for 6 weeks Result: Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon. |
| References |
| Molecular Formula | C26H44NNaO7S |
|---|---|
| Molecular Weight | 537.68 |
| Storage condition | -20°C |